This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Scarparo, C.
Right arrow Articles by Piccoli, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Scarparo, C.
Right arrow Articles by Piccoli, P.

 Previous Article  |  Next Article 

Journal of Clinical Microbiology, March 2004, p. 1109-1114, Vol. 42, No. 3
0095-1137/04/$08.00+0     DOI: 10.1128/JCM.42.3.1109-1114.2004
Copyright © 2004, American Society for Microbiology. All Rights Reserved.

Evaluation of the Fully Automated BACTEC MGIT 960 System for Testing Susceptibility of Mycobacterium tuberculosis to Pyrazinamide, Streptomycin, Isoniazid, Rifampin, and Ethambutol and Comparison with the Radiometric BACTEC 460TB Method

Claudio Scarparo,* Paolo Ricordi, Giuliana Ruggiero, and Paola Piccoli

Regional Mycobacteria Reference Centre, Laboratory of Clinical Microbiology and Virology, San Bortolo Hospital, Vicenza, Italy

Received 30 September 2003/ Returned for modification 23 October 2003/ Accepted 26 November 2003

The performance of the fully automated BACTEC MGIT 960 (M960) system for the testing of Mycobacterium tuberculosis susceptibility to streptomycin (SM), isoniazid (INH), rifampin (RMP), ethambutol (EMB), and pyrazinamide (PZA) was evaluated with 100 clinical isolates and compared to that of the radiometric BACTEC 460TB (B460) system. The agar proportion method and the B460 system were used as reference methods to resolve the discordant results for SM, INH, RMP, and EMB (a combination known as SIRE) and PZA, respectively. The overall agreements were 96.3% for SIRE and 92% for PZA. For SIRE, a total of 26 discrepancies were found and were resolved in favor of the M960 system in 8 cases and in favor of the B460 system in 18 cases. The M960 system produced 8 very major errors (VME) and 10 major errors (ME), while the B460 system showed 4 VME and 4 ME. No statistically significant differences were found. Both systems exhibited excellent performance, but a higher number of VME was observed with the M960 system at the critical concentrations of EMB and SM. For PZA, a total of eight discrepancies were observed and were resolved in favor of the M960 system in one case and in favor of the B460 system in seven cases; no statistically significant differences were found. The M960 system showed four VME and three ME. The mean times to report overall PZA results and resistant results were 8.2 and 9.8 days, respectively, for the M960 system and 7.4 and 8.1 days, respectively, for the B460 system. Statistically significant differences were found. The mean times to report SIRE results were 8.3 days for the M960 system and 8.2 days for the B460 system. No statistically significant differences were found. Twelve strains tested for SIRE susceptibility and seven strains tested for PZA susceptibility had been reprocessed because of contamination. In conclusion, the M960 system can represent a valid alternative to the B460 for M. tuberculosis susceptibility testing; however, the frequent contamination of the tests needs to be improved.

* Corresponding author. Mailing address: Regional Mycobacteria Reference Centre, Microbiology and Virology Laboratory, San Bortolo Hospital, Viale Rodolfi 37, Vicenza I-36100, Italy. Phone: 39 0444 993507. Fax: 39 0444 993963. E-mail: claudio.scarparo{at}tin.it.

Journal of Clinical Microbiology, March 2004, p. 1109-1114, Vol. 42, No. 3
0095-1137/04/$08.00+0     DOI: 10.1128/JCM.42.3.1109-1114.2004
Copyright © 2004, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Lin, S.-Y. G., Desmond, E., Bonato, D., Gross, W., Siddiqi, S. (2009). Multicenter Evaluation of Bactec MGIT 960 System for Second-Line Drug Susceptibility Testing of Mycobacterium tuberculosis Complex. J. Clin. Microbiol. 47: 3630-3634 [Abstract] [Full Text]  
  • Martin, A., von Groll, A., Fissette, K., Palomino, J. C., Varaine, F., Portaels, F. (2008). Rapid Detection of Mycobacterium tuberculosis Resistance to Second-Line Drugs by Use of the Manual Mycobacterium Growth Indicator Tube System. J. Clin. Microbiol. 46: 3952-3956 [Abstract] [Full Text]  
  • Abe, C., Kobayashi, I., Mitarai, S., Wada, M., Kawabe, Y., Takashima, T., Suzuki, K., Sng, L.-H., Wang, S., Htay, H. H., Ogata, H. (2008). Biological and Molecular Characteristics of Mycobacterium tuberculosis Clinical Isolates with Low-Level Resistance to Isoniazid in Japan. J. Clin. Microbiol. 46: 2263-2268 [Abstract] [Full Text]  
  • Jureen, P., Werngren, J., Toro, J.-C., Hoffner, S. (2008). Pyrazinamide Resistance and pncA Gene Mutations in Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 52: 1852-1854 [Abstract] [Full Text]  
  • Martin, A., Cubillos-Ruiz, A., Von Groll, A., Del Portillo, P., Portaels, F., Palomino, J. C. (2008). Nitrate reductase assay for the rapid detection of pyrazinamide resistance in Mycobacterium tuberculosis using nicotinamide. J Antimicrob Chemother 61: 123-127 [Abstract] [Full Text]  
  • van Klingeren, B., Dessens-Kroon, M., van der Laan, T., Kremer, K., van Soolingen, D. (2007). Drug Susceptibility Testing of Mycobacterium tuberculosis Complex by Use of a High-Throughput, Reproducible, Absolute Concentration Method. J. Clin. Microbiol. 45: 2662-2668 [Abstract] [Full Text]  
  • Garrigo, M., Aragon, L. M., Alcaide, F., Borrell, S., Cardenosa, E., Galan, J. J., Gonzalez-Martin, J., Martin-Casabona, N., Moreno, C., Salvado, M., Coll, P. (2007). Multicenter Laboratory Evaluation of the MB/BacT Mycobacterium Detection System and the BACTEC MGIT 960 System in Comparison with the BACTEC 460TB System for Susceptibility Testing of Mycobacterium tuberculosis. J. Clin. Microbiol. 45: 1766-1770 [Abstract] [Full Text]  
  • Somoskovi, A., Clobridge, A., Larsen, S. C., Sinyavskiy, O., Surucuoglu, S., Parsons, L. M., Salfinger, M. (2006). Does the MGIT 960 System Improve the Turnaround Times for Growth Detection and Susceptibility Testing of the Mycobacterium tuberculosis Complex?. J. Clin. Microbiol. 44: 2314-2315 [Full Text]  
  • Hall, L., Doerr, K. A., Harmsen, W. S., Wengenack, N. L., Roberts, G. D. (2006). Verification of Antimicrobial Susceptibility Testing of Mycobacterium tuberculosis.. J. Clin. Microbiol. 44: 1921-1921 [Full Text]  
  • Rusch-Gerdes, S., Pfyffer, G. E., Casal, M., Chadwick, M., Siddiqi, S. (2006). Multicenter Laboratory Validation of the BACTEC MGIT 960 Technique for Testing Susceptibilities of Mycobacterium tuberculosis to Classical Second-Line Drugs and Newer Antimicrobials.. J. Clin. Microbiol. 44: 688-692 [Abstract] [Full Text]  
  • Kruuner, A., Yates, M. D., Drobniewski, F. A. (2006). Evaluation of MGIT 960-Based Antimicrobial Testing and Determination of Critical Concentrations of First- and Second-Line Antimicrobial Drugs with Drug-Resistant Clinical Strains of Mycobacterium tuberculosis.. J. Clin. Microbiol. 44: 811-818 [Abstract] [Full Text]  
  • Piersimoni, C., Olivieri, A., Benacchio, L., Scarparo, C. (2006). Current Perspectives on Drug Susceptibility Testing of Mycobacterium tuberculosis Complex: the Automated Nonradiometric Systems. J. Clin. Microbiol. 44: 20-28 [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»